181 related articles for article (PubMed ID: 17319926)
1. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse.
Montano-Loza AJ; Carpenter HA; Czaja AJ
Am J Gastroenterol; 2007 May; 102(5):1005-12. PubMed ID: 17319926
[TBL] [Abstract][Full Text] [Related]
2. Remission in autoimmune hepatitis: what is it, and can it ever be achieved?
Al-Chalabi T; Heneghan MA
Am J Gastroenterol; 2007 May; 102(5):1013-5. PubMed ID: 17489784
[TBL] [Abstract][Full Text] [Related]
3. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis.
Czaja AJ; Menon KV; Carpenter HA
Hepatology; 2002 Apr; 35(4):890-7. PubMed ID: 11915036
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial.
Czaja AJ; Carpenter HA; Lindor KD
Hepatology; 1999 Dec; 30(6):1381-6. PubMed ID: 10573515
[TBL] [Abstract][Full Text] [Related]
5. Consequences of treatment withdrawal in type 1 autoimmune hepatitis.
Montano-Loza AJ; Carpenter HA; Czaja AJ
Liver Int; 2007 May; 27(4):507-15. PubMed ID: 17403191
[TBL] [Abstract][Full Text] [Related]
6. Serum immunoglobulins in patients with chronic hepatitis C: a surrogate marker of disease severity and treatment outcome.
Maruyama S; Hirayama C; Horie Y; Yorozu K; Maeda K; Inoue M; Fujii Y; Umeki K; Koda M
Hepatogastroenterology; 2007 Mar; 54(74):493-8. PubMed ID: 17523306
[TBL] [Abstract][Full Text] [Related]
7. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy.
Verma S; Gunuwan B; Mendler M; Govindrajan S; Redeker A
Am J Gastroenterol; 2004 Aug; 99(8):1510-6. PubMed ID: 15307869
[TBL] [Abstract][Full Text] [Related]
8. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease.
Montano-Loza AJ; Carpenter HA; Czaja AJ
Hepatology; 2007 Oct; 46(4):1138-45. PubMed ID: 17668882
[TBL] [Abstract][Full Text] [Related]
9. Clinical subgroup of autoimmune hepatitis type 1 sustaining remission without additional drugs.
Ohana M; Hajiro K; Okazaki K; Haga H; Kobashi Y
Hepatogastroenterology; 1998; 45(23):1667-72. PubMed ID: 9840126
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis.
Ichai P; Duclos-Vallée JC; Guettier C; Hamida SB; Antonini T; Delvart V; Saliba F; Azoulay D; Castaing D; Samuel D
Liver Transpl; 2007 Jul; 13(7):996-1003. PubMed ID: 17370335
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for recurrence of autoimmune hepatitis after liver transplantation.
Montano-Loza AJ; Mason AL; Ma M; Bastiampillai RJ; Bain VG; Tandon P
Liver Transpl; 2009 Oct; 15(10):1254-61. PubMed ID: 19790153
[TBL] [Abstract][Full Text] [Related]
12. Effects of serum aspartate aminotransferase levels in patients with autoimmune hepatitis influence disease course and outcome.
Al-Chalabi T; Underhill JA; Portmann BC; McFarlane IG; Heneghan MA
Clin Gastroenterol Hepatol; 2008 Dec; 6(12):1389-95; quiz 1287. PubMed ID: 18840547
[TBL] [Abstract][Full Text] [Related]
13. Deflazacort for long-term maintenance of remission in type I autoimmune hepatitis.
Rebollo Bernárdez J; Cifuentes Mimoso C; Piñar Moreno A; Caunedo Alvarez A; Salas Herrero E; Jiménez-Sáenz M; Herrerías Gutiérrez J
Rev Esp Enferm Dig; 1999 Sep; 91(9):630-8. PubMed ID: 10502711
[TBL] [Abstract][Full Text] [Related]
14. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis.
Czaja AJ; Carpenter HA
J Hepatol; 2004 Apr; 40(4):646-52. PubMed ID: 15030981
[TBL] [Abstract][Full Text] [Related]
15. Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4.
Czaja AJ; Carpenter HA; Moore SB
Liver Int; 2006 Jun; 26(5):552-8. PubMed ID: 16761999
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis.
Wang Q; Selmi C; Zhou X; Qiu D; Li Z; Miao Q; Chen X; Wang J; Krawitt EL; Gershwin ME; Han Y; Ma X
J Autoimmun; 2013 Mar; 41():140-5. PubMed ID: 23187010
[TBL] [Abstract][Full Text] [Related]
17. Histological findings in chronic hepatitis C with autoimmune features.
Czaja AJ; Carpenter HA
Hepatology; 1997 Aug; 26(2):459-66. PubMed ID: 9252159
[TBL] [Abstract][Full Text] [Related]
18. Frequency and nature of the variant syndromes of autoimmune liver disease.
Czaja AJ
Hepatology; 1998 Aug; 28(2):360-5. PubMed ID: 9695997
[TBL] [Abstract][Full Text] [Related]
19. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis.
Czaja AJ; Carpenter HA
Liver Int; 2003 Apr; 23(2):116-23. PubMed ID: 12654134
[TBL] [Abstract][Full Text] [Related]
20. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis.
Miyake Y; Iwasaki Y; Terada R; Takagi S; Okamaoto R; Ikeda H; Sakai N; Makino Y; Kobashi H; Takaguchi K; Sakaguchi K; Shiratori Y
J Hepatol; 2005 Dec; 43(6):951-7. PubMed ID: 16143423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
